Manidipino Viatris 20 mg tablets EFG

Package leaflet: Information for the user

Introduction

Package leaflet: Information for the user

Manidipino Viatris 20 mg tablets EFG

Read the entire leaflet carefully before you start taking this medicine, because it contains important information for you.

• Keep this leaflet as you may need to read it again.
• If you have any questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only and must not be given to other people, even if they have the same symptoms as you, because it could harm them.
• If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.

Contents of the leaflet

1. What Manidipino Viatris is and what it is used for
2. What you need to know before taking Manidipino Viatris
3. How to take Manidipino Viatris
4. Possible adverse effects
5. How to store Manidipino Viatris
6. Contents of the pack and other information

1. What Manidipino Viatris is and what it is used for

Manidipino Viatris tablets contain 20 mg of the active substance manidipino dihydrochloride, which belongs to a group of medicines called dihydropyridine calcium channel blockers.

Manidipino is indicated for the treatment of mild to moderate essential hypertension (high blood pressure).

Manidipino works by relaxing blood vessels, thereby reducing blood pressure.

2. What you need to know before taking Manidipino Viatris

Do not take Manidipino Viatris

• If you are allergic to manidipine, other dihydropyridines, or any other ingredient of this medicine (listed in section 6).
• If you have unstable angina (chest pain not caused by stress, physical exertion, or occurring at night) or have had a heart attack within the previous 4 weeks (myocardial infarction).
• If you have untreated congestive heart failure.
• If you have severe renal impairment (creatinine clearance <10 ml/min).
• If you have moderate to severe hepatic impairment.
• If you are a child.

Warnings and precautions

Consult your doctor or pharmacist before taking Manidipino Viatris

• If you have mild liver problems, as the effects of manidipine may be increased (see section 3 “How to take Manidipino Viatris”).
• If you are an elderly patient, a dose reduction may be recommended (see section 3 “How to take Manidipino Viatris”).
• If you are undergoing peritoneal dialysis.
• If you have heart problems such as issues with the left side of the heart valves causing reduced blood flow, heart failure on one side of the heart, or a very slow heartbeat due to electrical conduction problems in the heart not controlled by a pacemaker.

Other medicines and Manidipino Viatris

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines, including those obtained without a prescription, or medicines for the following conditions:

• High blood pressure, such as diuretics, beta-blockers, or prazosin.
• Viral or bacterial infections, such as ketoconazole, itraconazole, erythromycin, clarithromycin, or rifampicin.
• Mental disorders, such as antidepressants and antipsychotics.
• Epilepsy, such as phenytoin, carbamazepine, or phenobarbital.
• Chemotherapy and radiotherapy, such as amifostine.
• HIV treatment, such as protease inhibitors.
• Stomach problems, such as cimetidine.
• Irregular heartbeat (such as amiodarone, quinidine, digoxin).
• Muscle stiffness and limited movement, such as baclofen.
• Allergies (such as terfenadine, astemizole).
• Swelling or increased immune system activity, or when pituitary and adrenal glands are not functioning properly, such as corticosteroids or tetracosactide.
• Enlargement of the prostate gland, such as alfuzosin, doxazosin, tamsulosin, or terazosin.

Manidipino Viatris with food and drink

Do not drink alcohol or grapefruit juice during treatment with manidipine, as both alcohol and grapefruit juice may lower blood pressure.

Pregnancy and breastfeeding

Manidipine must not be taken during pregnancy. The use of manidipine should be avoided during breastfeeding, as it is unknown whether this medicine passes into breast milk. If treatment with manidipine is necessary, breastfeeding must be discontinued.

Fertility

Abnormalities in sperm heads have been reported, which may impair fertility in patients treated with medicines such as manidipine.

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, consult your doctor or pharmacist before taking this medicine.

Driving and using machines

This medicine may cause drowsiness; therefore, caution is advised when driving or operating machinery.

Manidipino Viatris contains lactose

If your doctor has informed you that you have an intolerance to certain sugars, consult your doctor before taking this medicine.

3. How to take Manidipino Viatris

Always follow exactly the instructions provided by your doctor or pharmacist for taking this medicine. If you have any doubts, consult your doctor or pharmacist.

If you notice that the effect of manidipine is too strong or too weak, consult your doctor or pharmacist.

Use in children and adolescents

Manidipino Viatris must not be used in children and adolescents.

Duration of treatment

Your doctor will tell you how long to take the medicine. Do not stop treatment before your doctor advises you to do so.

Method of administration

The tablets should be taken in the morning after breakfast, without chewing and with a small amount of liquid.

The recommended starting dose is 10 mg once daily.

If after 2–4 weeks of treatment the antihypertensive effect of manidipine is insufficient, your doctor may increase the dose to 20 mg once daily.

The break line is only intended to assist in splitting the tablet if you have difficulty swallowing it.

Elderly patients or patients with renal or hepatic impairment

If you are elderly or suffer from renal or hepatic impairment, your doctor may prescribe a lower dose (10 mg once daily).

If you take more Manidipino Viatris than you should

If you (or someone else) take a large number of tablets at the same time, or if you suspect a child has taken any of the tablets, contact the nearest hospital emergency department or your doctor immediately. As with other calcium channel blockers, overdose is expected to cause vasodilation, which could lead to a drop in blood pressure and an increased heart rate.

In case of overdose or accidental ingestion, contact your doctor or pharmacist immediately or call the Toxicology Information Service at telephone number: 91 562 04 20, stating the name of the medicine and the amount ingested.

If you forget to take Manidipino Viatris

If you miss a dose, take it as soon as possible and then take the following doses as prescribed.

Do not take a double dose to make up for a forgotten dose.

If you stop taking Manidipino Viatris

Before stopping Manidipino Viatris, contact your doctor.

If you have any questions about how to take this medicine, consult your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone experiences them.

The following serious adverse effects may occur while taking Manidipino Viatris. If any of these occur, consult your doctor or go to the nearest hospital immediately.

Very rare (may affect up to 1 in 10,000 people)

• Heart attack; in some patients with pre-existing angina, an increase in frequency, duration, and severity of episodes may occur.

Other possible adverse effects

Common (may affect up to 1 in 10 people)

• Headache.
• Dizziness.
• Vertigo.
• Swelling caused by fluid retention (edema).
• Fast or irregular heartbeat (palpitations).
• Hot flushes.

Uncommon (may affect up to 1 in 100 people)

• Tingling sensation in the skin.
• Weakness or lack of energy.
• Increased heart rate.
• Low blood pressure.
• Difficulty breathing.
• Malaise (nausea).
• Vomiting.
• Constipation.
• Dry mouth.
• Digestive disorders.
• Skin rashes.
• Eczema.
• Increase in liver enzymes and/or increase in kidney parameters (may be seen in blood tests).

Rare (may affect up to 1 in 1,000 people)

• Sleepiness.
• Somnolence.
• High blood pressure.
• Stomach pain.
• Abdominal pain.
• Skin redness.
• Itching and irritability.
• Increase in bilirubin, which may be detected in blood tests.
• Diarrhea.
• Loss of appetite (anorexia).
• Yellowish discoloration of the skin or the whites of the eyes (jaundice).

Very rare (may affect up to 1 in 10,000 people)

• Inflammation or alteration of the gums, which usually resolves upon discontinuation of treatment.

Frequency not known (cannot be estimated from the available data)

• Skin peeling or shedding, small spots on the skin.
• Extrapyramidal syndrome has been reported with other medicines of this class.
• Muscle pain.
• Breast enlargement, with or without tenderness, in men (gynecomastia).
• Cloudy fluid (when performing dialysis through a tube in the abdomen).

Reporting of adverse effects:

If you experience any adverse effects, consult your doctor or pharmacist, even if they are possible adverse effects not listed in this leaflet. You may also report them directly via the Spanish Pharmacovigilance System for Human Medicines: https://www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Manidipino Viatris

Keep this medicine out of the sight and reach of children.

Do not take manidipino after the expiry date stated on the packaging after EXP. The expiry date refers to the last day of the month indicated.

This medicine does not require any special storage conditions.

Medicines must not be disposed of via wastewater or household waste. Return unused medicines and their containers to the SIGRE point at your pharmacy. If you are unsure, ask your pharmacist how to dispose of medicines and containers you no longer need. This will help protect the environment.

6. Information provided

Contents of Manidipino Viatris:

The active substance is manidipine dihydrochloride 20 mg.

Each tablet contains 20 mg of manidipine dihydrochloride.

The other components are monohydrate lactose (see section 2 “Manidipino Viatris contains lactose”), corn starch, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, magnesium stearate, riboflavin.

Appearance of Manidipino Viatris and contents of the pack

The tablets are oval-shaped, convex, yellow in colour, with a central score line.

Manidipino Viatris is available in packs containing 14, 28, 30, 56, 84, 90, 98 and 112 tablets.

Only certain pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder

Viatris Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland

Manufacturer

Abiogen Pharma SpA
Via Meucci 36, Ospedaletto
56014 Pisa - Italy

or

Doppel Farmaceutici S.r.l.
Via Volturno, 48
20089 Quinto de Stampi, Rozzano, Milano
Italy

or

Vamfarma S.r.l.
Via Kennedy, 5
26833 Comazzo
Italy

For further information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

Viatris Pharmaceuticals, S.L.U.
C/ General Aranaz, 86
28027 - Madrid
Spain

This medicinal product has been authorised in the European Economic Area member states under the following names:

Spain: Manidipino Viatris 20 mg tablets EFG
France: Manidipine Viatris 20 mg comprimé

Date of latest revision of this information: November 2024

Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) https://www.aemps.gob.es/